The bill is expected to receive a final vote in the Arizona House soon, and opponents are actively working to gather votes against it. This is a critical moment for supporters to speak up.

Under SB 1713, pharmacists operating under a statewide written protocol approved by the Arizona State Board of Pharmacy would be able to order and interpret FDA-authorized, CLIA-waived tests and initiate treatment for certain conditions, including:

• Influenza
• Group A streptococcus
• COVID-19
• HIV pre- and post-exposure prophylaxis (PrEP and PEP)
• Certain public health threats

This vital legislation would give Arizonans a practical, patient-centered option for receiving appropriate testing and treatment — especially when timely care is critical.

Pharmacists are among the most accessible and trusted healthcare professionals, with frequent touchpoints in their communities. Their extensive training in patient assessment, pharmacology, and disease management prepares them to provide these services safely and effectively.

Importantly, SB 1713 does not replace primary care providers. Instead, it strengthens coordination within the healthcare system and expands access to care for routine, test-confirmed conditions — particularly in rural and underserved communities facing provider shortages and long wait times.

Please contact your Arizona House members today and urge them to support SB 1713.